When is the best time to take pomalidomide?

Pomalidomide is an immunomodulator that is mainly used to treat patients with relapsed or refractory multiple myeloma (RRMM). Its clinical efficacy not only depends on the dose and combination regimen, but also is closely related to the time and method of administration.

According to pharmacokinetic studies, pomalidomide is well absorbed orally and has high bioavailability, but food intake has a certain impact on its peak drug concentration (Cmax) and overall exposure (AUC). Compared with the fasting state, taking it with food can cause Cmax to decrease by about 27%, AUC to decrease by about 8%, and delay the time for peak blood concentration to reach about two to three hours. Therefore, in order to ensure the stable blood concentration of the drug in the body and exert the best efficacy, clinical practice usually recommends that patients take the drug orally at a relatively fixed time every day. Fasting is not strictly required, but the medication time should be kept as consistent as possible to avoid differences in efficacy caused by fluctuations in blood drug concentration.

The significance of taking medicine at a fixed time is not only to maintain blood drug concentration, but also to facilitate long-term treatment management. Pomalidomide is often given orally once daily in combination with low-dose dexamethasone, with consistency across successive treatment cycles to aid in immune system modulation and tumor cell clearance. In addition, taking medicine at a fixed time also allows doctors to monitor the patient's efficacy and adverse reactions, adjust the dose in a timely manner or take auxiliary intervention measures, such as anticoagulation prevention or infection protection. It should be noted that although the drug can be taken with food, high-fat meals or large meals should be avoided to avoid delaying drug absorption and affecting the peak blood concentration, thereby reducing the timeliness of the immunomodulatory effect.

Taken together, for patients with relapsed and refractory multiple myeloma, stable drug exposure can ensure the continued enhancement of T cell and NK cell activity, while maximizing the inhibitory effect on tumor cells through CRBN-mediated degradation of key transcription factors.

Reference materials:https://en.wikipedia.org/wiki/Pomalidomide